Patent ID: 7413736

Claim:
A therapeutic composition comprising a humanized anti-idiotype antibody or antibody fragment comprising heavy chain variable region sequences CDR-1 (NYWMT, SEQ ID NO:1), CDR-2 (SITSTGGGTYHAESVKG, SEQ ID NO:2), and CDR-3 (DDYGGQSTYVMDA, SEQ ID NO:3), and light chain variable region sequences CDR1 (RASQDIGNYLR, SEQ ID NO:4), CDR2 (GATNLAA, SEQ ID NO:5), and CDR3 (LHHSEYPYT, SEQ ID NO:6) and humanized FR region sequences, conjugated to a soluble immunogenic carrier protein, wherein the therapeutic composition is effective to stimulate an immune response in a patient against a cancer characterized by expression of CEA.